Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-20-041644)

Filing Details

Accession Number:: 0001209191-20-041644
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-08 12:30:41
Reporting Period:: 2020-07-06

Accepted Time:: 2020-07-08 12:30:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397266	K Matthew Fust	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-06	6,181	$21.00	19,731	No	4	M	Direct
Common Stock	Disposition	2020-07-06	6,181	$90.00	13,550	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-06	6,181	$0.00	6,181	$21.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2024-01-29	No	4	M	Direct

Footnotes

The exercise and sale reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The option vested with respect to 1/36th of the shares monthly from the grant date of January 29, 2014 such that option fully vested on the third anniversary of the grant date.